Abstract Long-lasting siRNA-based down-regulation of gene of interest can be achieved by lentiviral-based expression vectors driving the production of short hairpin RNA (shRNA). We investigated an attractive therapeutic approach to target the expression of proinflammatory GMF by using lentiviral vector encoding GMF-specific shRNA to reduce GMF levels in the spinal cord and brain of mice. To determine the effect of GMF-shRNA on GMF protein levels, we performed quantitative ELISA analysis in brain and in thoracic, cervical and lumbar regions of spinal cord from mice followed by GMF-shRNA (G-shRNA) or control shRNA (C-shRNA) treatments. Our results show a marked reduction of GMF protein levels in brain and spinal cord of mice treated with GMF-shRNA compared to control shRNA treatment. Consistent with the GMF protein analysis, the immunohistochemical examination of the spinal cord sections of EAE mice treated with GMFshRNA showed significantly reduced GMF-immunoreactivity. Thus, the down-regulation of GMF by GMF-shRNA was efficient and wide spread in CNS as evident by the significantly reduced levels of GMF protein in the brain and spinal cord of mice.
Introduction
We have shown earlier [21] [22] [23] that glia maturation factor (GMF) plays a key role in regulating immune responses in the central nervous system (CNS) by way of proinflammatory cytokines/chemokines production and regulating the cytokine mediated pathways. In addition, we have also demonstrated that GMF-deficient mice failed to develop experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), induced by the encephalitogenic MOG 35-55 peptide [24, 25] . Our earlier studies [20, [22] [23] [24] [25] clearly indicated that GMF plays a critical role in immune regulation and progression of CNS inflammation. Our long-term goal is to down-regulate the deleterious effects of GMF in the CNS thereby preventing the propagation of CNS inflammation leading to a successful GMF-inhibitor-based therapy for MS; therefore, efficient and sustained silencing of GMF expression in vivo is critical.
Sequence-specific inhibition of gene expression by double-stranded RNA is referred to RNA interference (RNAi). RNA interference can be brought about by either long double-stranded or by short interfering (si) RNAs. Recently, short interfering RNAs (siRNA) have been successfully used for sequence-specific inhibition of targeted gene expression in cultured cells and in vivo. In this study, we have examined the potential for an efficient and sustained down-regulation of GMF expression in the CNS by injecting GMF-specific siRNA and demonstrated a significant reduction of shRNA-mediated GMF expression in the spinal cord and brain of injected mice. Our overall data demonstrate that RNAi can achieve specific GMF silencing in vivo.
Experimental Procedures

Reagents
Myelin oligodendrocyte glycoprotein peptide 35-55, complete Freund's adjuvant and pertussis toxin were purchased from Sigma-Aldrich, St. Louis, MO. Adenovirus constructs were prepared at the University of Iowa Gene Transfer Vector Core as described earlier [4, 10] , using a replication-defective adenovirus (serotype 5) vector encoding the reporter gene for bacterial b-galactosidase. shRNA Delivery in Mice
We used a lentivectors expressing GMF-specific short hairpin RNA (shRNA, Open BioSystems, Lafayette, CO, USA) that efficiently silenced expression of the GMF protein gene in primary brain cells and in mice in vivo. Hairpin mouse GIPZ lentiviral GMF-shRNAmir sequence is shown: TGCTGTTGACAGTGAGCGAGGAAATCA TCTTCATAGTAATTAGTGAAGCCACAGATGTAATT ACTATGAAGATGATTTCCCTGCCTACTGCCTCGGA.
Vector sequence followed by sense (GMF) sequence (underlined), loop sequence, and antisense (GMF) sequence (italic underlined). The shRNA expression lentivirus was generated as described by Xia et al. [19] , and each mouse received i.v injections of the lentiviral preparation (1 9 10 11 transduction units) in 50 ul.
Histological Assessment
At the peak of the disease, three mice from each experimental group were anesthetized by intraperitoneal injection of sodium pentobarbital and transcardially perfused with PBS and by 4% paraformaldehyde in phosphate buffer as described earlier [3, [15] [16] [17] [18] . The brain was removed and rinsed thoroughly with normal saline. For histochemical staining of b-galactosidase activity, the brains were placed in 2% paraformaldehyde and 0.2% glutaraldehyde in PBS, and then rinsed with PBS. The whole brain or coronal sections were incubated in 5-bromo-4-chloroindolyl-b-D-galactopyranoside (X-Gal) solution (1 h at room temperature), rinsed in normal saline solution, and then post fixed with 7% buffered formalin. The fixed tissue was then processed for paraffin embedding, and sections were examined for positive staining of b-galactosidase by light microscopy.
Enzyme-Linked Immunosorbent Assay (ELISA)
The analysis of GMF protein concentration was estimated by sandwich immuno-assay procedure as described earlier [21] [22] [23] . Briefly, to 96-well microtiter ELISA plates precoated with anti-GMF capture antibodies, and samples were added and incubated overnight at 4°C followed by washing. Corresponding biotinylated antibodies, horseradish peroxidase-conjugated streptovidin and TMB substrate used to develop a yellow color and read by a microplate reader at 450 nm. The concentration of GMF was estimated from a standard curve generated with each run. The lower detection limits of these ELISA are in the range of 5-10 pg/mg of protein. ELISA data are presented as mean values ± standard deviations.
Statistical Analysis
Statistical significance was assessed with one-way ANOVA followed by Tukey's procedure using SigmaStat software (SPP, Chicago, IL, USA). A value of p\0.05 was considered statistically significant.
Results
Virus-Mediated Gene Transfer to Brain and Spinal Cord
An efficient transgene expression-based strategy for treating EAE would require an efficient delivery of the therapeutic agent to CNS. Therefore, we examined transgene expression in CNS after injection of a replication-deficient recombinant adenovirus expressing b-galactosidase (AdCMV-LacZ) into the mouse. The brain and spinal cord from three mice in each group were examined 2 days after injection by histochemical staining. Histochemical analysis for b-galactosidase was carried out by incubating brain, spinal cord, or tissue sections in 5-bromo-4-chloro-indolylb-D-galactopyranoside (X-Gal) solution, rinsed in PBS, and fixed with formalin. Strong X-gal staining was observed on the ventral and dorsal surface of the brain along the cerebral arteries (Fig. 1 ). Brain and spinal cord sections were examined for positive staining of X-gal (blue) by light microscopy (Figs. 2, 3 ). These results demonstrate the widespread expression of b-galactosidase gene in brain and spinal cord of mice following i.v. administration.
GMF-shRNA-Mediated Efficient Down-Regulation of GMF Expression in Brain and Spinal Cord
Long-lasting siRNA-based down-regulation of gene of interest can be achieved by lentiviral-based expression vectors driving the production of short hairpin RNA (shRNA). We investigated an attractive therapeutic approach to target the expression of proinflammatory GMF by using lentiviral vector encoding GMF-specific shRNA to reduce GMF levels in the spinal cord and brain of mice with EAE.
To determine the effect of GMF-shRNA on GMF protein levels, we performed quantitative ELISA analysis in brain and in thoracic, cervical and lumbar regions of spinal cord from mice immunized with MOG 35-55 followed by GMF-shRNA (G-shRNA) or control shRNA (C-shRNA) treatments (six mice in each group). Results in Fig. 4 show a marked reduction of GMF protein levels in brain and spinal cord of mice treated with GMF-shRNA compared to control shRNA treatment. The down-regulation of GMF by GMF-shRNA was further shown by the reduced GMF-immunoreactivity in the spinal cord sections of EAE mice treated with immunohistochemical methods (Fig. 5a ).
The number of GMF-immunoreactive cells in MOGimmunized, and sixteen and twenty-four days following GMF-shRNA treated groups are shown in Fig. 5b . The GMF-shRNA treated group showed marked reduction in GMF-immunoreactive cells. We counted the GMF-positive cells on cryostat sections immunostained with GMF-antibody using 209 magnifications. The average of three separate cell counts from three mice per group was used. Thus, the down-regulation of GMF by GMF-shRNA was efficient and wide spread in CNS as evident by the significantly reduced levels of GMF protein in the brain and spinal cord of EAE mice.
Discussion
Adenoviral and lentiviral vectors are shown to be effective in sustained siRNA expressions in specific regions of brain [3, 5, 6, 8, 19, 26] . Furthermore, Davidson et al. [6] have shown sustained gene expression via adenoviral vector for 15 weeks following stereotactic intracranial delivery. Similar results were obtained using lentiviral vectors. In another study, Raoul et al. [14] demonstrated that intraspinal injection of lentiviral constructs for SOD1 siRNA in mouse led to silencing of SOD1 gene for about 120 days. Moreover, the intraspinal delivery resulted in transduction of both neurons and glia [14] . It has been shown by Dillon et al. [7] that a sustainable silencing of gene expression could be achieved by shRNA once integrated into the genome. Lentiviral vectors have a major advantage over the other systems that they could infect post mitotic cells such as brain cells [12, 13] . These studies clearly demonstrate the feasibility of using viral vectors and in particular lentiviral vectors for therapy in brain. This is the first report showing that GMF-specific shRNA is capable of efficiently inhibiting expression of GMF in vivo. In this study, we have demonstrated that GMF-shRNA mediate efficient down-regulation of GMF expression. Small interfering RNAs (siRNAs) are known to cause sequence-specific gene silencing [11] and therefore is ideal for silencing genes that cause various diseases of the central nervous system. Recently, gene therapy strategies were tested widely in the field of autoimmune disease [1, 2, 9] . In order to design an efficient strategy based on transgene expression for treating EAE/MS, it is necessary to have an efficient delivery system of the therapeutic agent to CNS. These reagents are delivered by chemically synthesized small interfering RNAs or by viral vectors carrying genes of interest. In this regard we first examined transgene expression in the CNS of the mouse after injection of a replication-deficient recombinant adenovirus expressing b-galactosidase (AdCMV-LacZ). We observed wide expression of b-galactosidase on the ventral surface of the brain of mouse following injection of AdCMV-LacZ. Histochemical analysis for b-galactosidase revealed intense staining in the major cerebral arteries and also in smaller arteries. Next, to test specific silencing of GMF in vivo, we designed shRNA construct to express a shRNA that can specifically silence GMF gene. Our data demonstrate that lentiviral-mediated delivery of RNAi can achieve specific GMF silencing in vivo. Quantitative ELISA analysis confirmed that lentiviral-mediated delivery of GMF-shRNA led to decreased levels of GMF protein in the CNS of injected mice.
In summary, we explored an attractive therapeutic approach to target the expression of proinflammatory GMF by using GMF-specific shRNA to reduce levels of GMF expression in the spinal cord and brain of mice. 
